Company Encyclopedia
View More
name
Cassava Sciences
SAVA.US
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. Cassava Sciences, Inc. was formerly known as Pain Therapeutics, Inc.
4.514 T
SAVA.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Cassava Sciences Inc - FDA Requires Additional Information From Cassava For Clinical Study - SEC Filing

    Dec 3 (Reuters) - Cassava Sciences Inc:* CASSAVA SCIENCES INC - FDA REQUIRES ADDITIONAL INFORMATION FROM CASSAVA FOR CLINICAL STUDY - SEC FILING* CASSAVA SCIENCES INC - PREPARES TO INITIATE PROOF-OF-CONCEPT STUDY IN FIRST HALF OF 2026 FOR SIMUFILAM - SEC FILING* CASSAVA SCIENCES INC - EXPECTS FORMAL LETTER FROM FDA DETAILING ISSUES ON CLINICAL TRIAL FOR SIMUFILAM - SEC FILING Source text: Further company coverage:

    Reuters·
    US
    SAVA
    +7.10%
    Reuters·
    US
    SAVA
    +7.10%

    Cassava Sciences Faces FDA Request for More Data on Simufilam Epilepsy Trial

    Cassava Sciences Inc. has submitted an IND application to the FDA for a simufilam epilepsy trial. The FDA requested more data to assess risks and support the study's initiation. Cassava plans to address these issues and aims to start the trial in early 2026. This news was generated by AI and is not financial advice.

    Reuters·
    US
    SAVA
    +7.10%
    Reuters·
    US
    SAVA
    +7.10%

    Cassava Sciences rises 10% after market close on CEO stock buy

    Cassava Sciences' stock rose 10% in after-market trading after CEO Richard Barry purchased 150,000 shares worth approximately $414K, increasing his total holdings to over 938,000 shares.

    MSN·
    US
    SAVA
    +7.10%
    MSN·
    US
    SAVA
    +7.10%

    Cassava Sciences CEO Richard Barry Acquires Common Shares

    Cassava Sciences CEO Richard Barry has acquired common shares of the company. The acquisition was reported through a filing accessible via EDGAR, the SEC's system. The news was generated by Public Technologies using AI and is for informational purposes only.

    Reuters·
    US
    SAVA
    +7.10%
    Reuters·
    US
    SAVA
    +7.10%

    Biotech Stocks Swing After Hours: Delcath Rises On Buyback, BioVie And Cassava Rebound

    After-hours trading saw biotech stocks like Delcath Systems rise due to a $25 million buyback announcement, reflecting confidence in its long-term outlook. BioVie, Cassava Sciences, and Enlivex Therapeutics also rebounded despite no new headlines. Cassava's rise follows its Q3 results showing a reduced net loss and strong cash position.

    rttnews·
    US
    DCTH
    +3.73%
    US
    SAVA
    +7.10%
    US
    ENLV
    +6.42%
    rttnews·
    US
    DCTH
    +3.73%
    US
    SAVA
    +7.10%
    US
    ENLV
    +6.42%
    © 2025 Longbridge｜Disclaimer